NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes. - Wikidata - awgldk - TriplyDB

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

http://www.wikidata.org/entity/Q33393647

about

Erythropoiesis-stimulating agents for myelodysplastic syndromes Deferasirox for managing iron overload in people with myelodysplastic syndrome Erythropoiesis-stimulating agents for myelodysplastic syndromes Treatment of higher risk myelodysplastic syndrome patients unresponsive to hypomethylating agents with ON 01910.Na Transfusion Thresholds, Quality of Life, and Current Approaches in Myelodysplastic Syndromes Spotlight on decitabine for myelodysplastic syndromes in Chinese patients Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management Beyond hypomethylating agents failure in patients with myelodysplastic syndromes Revisiting the case for genetically engineered mouse models in human myelodysplastic syndrome research Some aspects of allogeneic stem cell transplantation in patients with myelodysplastic syndrome: advances and controversy Myelodysplastic syndromes: what do hospitalists need to know?Iron chelation therapy in myelodysplastic syndromes: where do we stand?Decision points in the treatment of transfusional iron overload in patients with myelodysplastic syndromes: why, when, and how to chelate.Phase I clinical trial of oral rigosertib in patients with myelodysplastic syndromes.Blood disorders typically associated with renal transplantation Effects of decitabine on megakaryocyte maturation in patients with myelodysplastic syndromes.Hematologic complications, healthcare utilization, and costs in commercially insured patients with myelodysplastic syndrome receiving supportive care.Tumor suppressor p53 protein expression: prognostic significance in patients with low-risk myelodysplastic syndrome.Current therapy of myelodysplastic syndromes There's risk, and then there's risk: The latest clinical prognostic risk stratification models in myelodysplastic syndromes.Distinct clinical and experimental characteristics in the patients younger than 60 years old with myelodysplastic syndromes.Revised international prognostic scoring system for myelodysplastic syndromes.NRAS mutations with low allele burden have independent prognostic significance for patients with lower risk myelodysplastic syndromes.Establishment and validation of an updated diagnostic FCM scoring system based on pooled immunophenotyping in CD34+ blasts and its clinical significance for myelodysplastic syndromes.The prognostic impact of mutations in spliceosomal genes for myelodysplastic syndrome patients without ring sideroblasts Biosimilar epoetin α is as effective as originator epoetin-α plus liposomal iron (Sideral®), vitamin B12 and folates in patients with refractory anemia: A retrospective real-life approach.Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.The challenge of individualised risk assessment and therapy planning in elderly high-risk myelodysplastic syndromes (MDS) patients.Validation of a prognostic model and the impact of mutations in patients with lower-risk myelodysplastic syndromes Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges The impact of hypomethylating agents on the cost of care and survival of elderly patients with myelodysplastic syndromes Targeting of the bone marrow microenvironment improves outcome in a murine model of myelodysplastic syndrome.Managing myelodysplastic syndromes in very old patients: a teaching case report.Efficacy and safety of extended dosing schedules of CC-486 (oral azacitidine) in patients with lower-risk myelodysplastic syndromes.Reproducibility of the World Health Organization 2008 criteria for myelodysplastic syndromes.Non-hematologic predictors of mortality improve the prognostic value of the international prognostic scoring system for MDS in older adults.Flow Cytometry in the Diagnosis of Myelodysplastic Syndromes Analysis of the efficacy of lenalidomide in patients with intermediate-1 risk myelodysplastic syndrome without 5q deletion.Lenalidomide performance in the real world: patterns of use and effectiveness in a Medicare population with myelodysplastic syndromes.Role of reduced-intensity conditioning allogeneic hematopoietic stem-cell transplantation in older patients with de novo myelodysplastic syndromes: an international collaborative decision analysis

P2860

Q24186244-9533F331-6FBA-4F6C-B7CF-8E7C5944E985 Q24193067-7D072A0E-285E-4A51-B2D4-3553C69C6627 Q24202526-210546BC-4A4E-4B4B-9EF0-CC8C9F6D5AE6 Q24597616-21A6E6F7-B678-41E7-80B7-F83DCFF667DB Q26748281-EAA8BA5B-C0EB-4F37-8FE5-F5B02CD12CF3 Q26778454-BF7D347C-59FF-4BA7-8E02-49D27B8ABB0A Q26796240-003E5C0D-DE56-4397-9F96-EBA625E8E032 Q26827079-31D98B84-F4B4-4283-8CF8-57DF7E46E44C Q26859843-FEE6FA2C-9063-4EC7-AE9C-B1C020012339 Q27010653-46450F2D-0994-4144-9731-5660F002D59F Q27011372-3C8F8EDB-6184-40F6-9A5D-1107E089AC96 Q27011747-3C8766FE-3CA3-4188-8981-6B1E2B395D3B Q30240190-0B49976D-82BE-4F4F-BE42-60F451E6FD00 Q33162921-F4B2497A-D86C-46C7-95BB-120D1A1A0637 Q33421793-2A147289-1CC4-4E15-8F8B-328CA7FD7594 Q33431466-EF427123-87AC-4D37-B809-4BFB45F96240 Q33652781-BD8615D8-B849-43FD-89A3-D33C41B6F17D Q33945004-4DA154FD-9376-4433-A47C-68649FA33B97 Q34013796-D454E6A7-FFCC-4BCF-9273-B8DAF2681C02 Q34049017-2D249AE2-1F79-4BCE-A414-717CB24E6CDF Q34612063-41CB4836-132B-4588-9873-AA6634C0AF95 Q34639717-A6321EB4-9043-4E97-B05E-D6B5A744855D Q34740986-1180775F-36F0-44B1-97E4-BA198796FA89 Q35099645-CBACD4E6-B604-444E-BFAB-3F63BF75A51F Q35675958-B819C3A3-9458-4E9F-8DBC-D1369F96EA91 Q35802841-558706D7-AC4D-4C20-94DD-65542B1861C5 Q36036263-DB7DFAE6-66DE-429C-BBE8-790E0F574099 Q36138278-01B8CFE5-9F8E-4F37-B19D-122500108FB1 Q36222935-5A0148DA-200E-4559-A4E2-F50FAD34E756 Q36266642-7075BC5C-AACD-4C1C-90A8-21D46EEC9366 Q36280941-21A777B5-2B07-4DBD-9F3E-12A62504B96F Q36547805-E3156202-85AD-4B16-AA0D-0A955ADCB0C5 Q36772626-C0DDD2A8-ABE9-49BC-ADE9-5FFA12DD7368 Q36799188-F21016EC-7F31-4D6D-9C78-2D05E44EA97D Q36862492-391C87DF-31D9-45F5-9A97-490AAA545C0A Q36879957-309B3B44-8B7A-49C7-BF91-24A3E08C26B7 Q37155338-224162C8-D221-4624-B29D-6426388BF9FF Q37207084-B03E3D31-B24E-4878-B9B1-82A809AF17E8 Q37248775-5A6BD270-3279-4DA4-86FC-8BF9BD9956B4 Q37301516-2247CDDE-B58A-4C1A-9162-42F2B90C703C

P2860

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

http://www.wikidata.org/entity/Q33393647

description

2011 nî lūn-bûn

@nan

2011 թուականի Յունուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի հունվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

@ast

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

@en

type

label

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

@ast

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

@en

prefLabel

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

@ast

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

@en

P1433

Q33393647-5964774F-AFA0-4000-A855-7F6CF7846904

P1476

Q33393647-180A074C-DE08-4E1A-839D-145042C0E053

P2093

Q33393647-00196164-DE50-463E-A96F-0C8096849507

Q33393647-01C04899-3DF0-4FF8-BF3E-43E3F9FC34A0

Q33393647-03F91C7A-C952-4CBE-BB2A-BCD28B711C41

Q33393647-0E600D3B-3C3B-4EEF-96F3-EDA04C009778

Q33393647-1493A724-C668-4137-AF2C-BC813F74462D

Q33393647-2A3FB658-797E-4619-AFA9-E72EEC229DC5

Q33393647-2B436D71-B60C-443C-800E-9FA381E8C4D6

Q33393647-32CE614B-DF75-4B8D-9FB4-8FDED479964A

Q33393647-37A9EB45-52DF-4233-BC89-1E7183F1535B

Q33393647-3F760125-10E8-486A-A65B-7926A4B8969F

P2860

Q33393647-014BFB21-A51F-4BDF-8BCC-A381A21BEF83

Q33393647-01F4659D-7AD9-4759-A39D-DE513DA0A06E

Q33393647-0AC8DC4F-B450-4966-A98D-7FA9754D208E

Q33393647-10CE59E5-4EA3-4B25-9A61-3955C99D910E

Q33393647-1147261D-78D6-4507-93F9-9C588BA9431D

Q33393647-1524D78F-3927-41CA-89B6-047E6185E90D

Q33393647-195881D9-DDB3-4A39-9711-02BC9A5DC7A9

Q33393647-1B4591EC-4028-4D9B-899B-C902E438D928

Q33393647-1C3104C0-6CC8-423D-9132-6672DD1E93FB

Q33393647-1DCC3CC0-03F8-418A-9C73-E2B788A4A2E0

P304

Q33393647-5C16FD43-2E3F-4FE4-AEDC-2CB54437E2C5

P31

Q33393647-F4EB43B8-A99D-472A-84CC-E289D665A195

P356

Q33393647-81624A28-76D6-4676-A0FC-8F8D2BD0AF2B

P433

Q33393647-EB59534A-D88C-48D9-8D99-A417A7F4CAF1

P478

Q33393647-0F72BE27-E3CE-4945-83D3-2A28489766B4

P50

Q33393647-50619B02-DCBE-4439-9AD4-18D8A2088DF4

Q33393647-62731F54-02AA-4934-AFD3-EAD9E2A6A1CF

Q33393647-E307CD25-B9A3-4740-BBBD-CFEE6A866E07

Q33393647-E7E6B368-F7EB-4599-BC75-6CBD7E76C7C2

P577

Q33393647-33216F61-21C5-482D-B8B1-2C4C8DD94B9C

P698

Q33393647-27BCB880-0829-4283-BF46-B28CAE62F5DB

P932

Q33393647-C07A3D48-EBA7-4EFF-AC17-89977EC8BBE0

P356

JNCCN.2011.0005

P1433

Journal of the National Comprehensive Cancer Network

P1476

NCCN Clinical Practice Guidelines in Oncology: myelodysplastic syndromes.

@en

P2093

Carlos M De Castro

http://www.w3.org/2001/XMLSchema#string

David Head

http://www.w3.org/2001/XMLSchema#string

Eyal Attar

http://www.w3.org/2001/XMLSchema#string

James E Thompson

http://www.w3.org/2001/XMLSchema#string

James M Foran

http://www.w3.org/2001/XMLSchema#string

John M Bennett

http://www.w3.org/2001/XMLSchema#string

Karin Gaensler

http://www.w3.org/2001/XMLSchema#string

Lori J Maness

http://www.w3.org/2001/XMLSchema#string

Margaret R O'Donnell

http://www.w3.org/2001/XMLSchema#string

Mark A Schroeder

http://www.w3.org/2001/XMLSchema#string

P2860

The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

The World Health Organization (WHO) classification of the myeloid neoplasms

Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta

Proposals for the classification of the myelodysplastic syndromes

Decitabine improves patient outcomes in myelodysplastic syndromes: results of a phase III randomized study

International scoring system for evaluating prognosis in myelodysplastic syndromes

Noninvasive measurement of iron: report of an NIDDK workshop.

Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience.

Efficacy of lenalidomide in myelodysplastic syndromes.

P304

30-56

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.6004/JNCCN.2011.0005

http://www.w3.org/2001/XMLSchema#string

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

9

http://www.w3.org/2001/XMLSchema#string

P50

Clara D. Bloomfield

Guillermo Garcia-Manero

National Comprehensive Cancer Network

Hans Joachim Deeg

P577

2011-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21233243

http://www.w3.org/2001/XMLSchema#string

P932

3768131

http://www.w3.org/2001/XMLSchema#string